Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
1999-09-13
2001-01-09
Badio, Barbara (Department: 1616)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
C514S934000
Reexamination Certificate
active
06172053
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to a therapeutic composition for the treatment of viral infections and a method of administration thereof. More particularly, the invention relates to a therapeutic composition including a substantially water soluble local anesthetic of the ester type injectable and a water soluble glucocorticoid injectable, and to the method of administering said composition to an infected patient.
BACKGROUND OF THE INVENTION
In both Third-world and developing countries and also in developed countries, there is a prevalent need for an economical yet effective viral treatment to both ease human suffering and save lives. The present invention relates directly to both of these needs since it has been compassionately used to treat and/or cure a number of known pathogenic viruses, including but not limited to human immunodeficiency virus (HIV) causing acquired immunodeficiency syndrome (AIDS), Dengue fever virus, influenza virus, rhinovirus causing common colds, herpes zoster virus, mumps virus, measles virus, hepatitis virus, conjunctivitis virus, rabies virus, chickenpox virus and other viruses found in equatorial environments common to Third-World and developing countries but also found with increasing prevalence in industrialized nations. To the best of the inventor's knowledge, in medical textbooks or in current clinical practice, there is no treatment, cure or vaccine for the Dengue fever virus.
This invention comes about after many years of field testing, and now over two years of clinical studies at the Fabunan Medical Clinic located in the province of Zambales, the Philippines in Southeast Asia. Each known virus that has been treated with this composition has shown a remarkably significant improvement and/or curative result with no serious side effects. Routine cases were clinically diagnosed and then treatment began. A patient usually improved and recovered within seventy two hours but, sometimes, more time was needed.
DESCRIPTION OF THE PRIOR ART
U.S. Pat. No. 5,492,901 issued to Dr. Ruben G. Fabunan, the present inventor, discloses an envenomation antidote for therapeutic use in the treatment of venomous animal bites or stings. The antidote is administered by intramuscular injection and subcutaneous injection along with a slow intravenous injection. The antidote is comprised of procaine hydrochloride with epinephrine and dexamethasone sodium phosphate. The present invention discloses a formulation of procaine hydrochloride without epinephrine and dexamethasone sodium phosphate and is administered only intramuscularly for, surprisingly, the treatment of viral diseases.
U.S. Pat. No. 5,922,340 discloses a glucocorticosteroid used to prolong the duration of a local anesthetic by using a controlled release material.
U.S. Pat. No. 5,837,729 discloses the use of acetaminophen (Tylenol), an analgesic without anti-inflammatory activity, and derivatives thereof, in the treatment and prevention of HIV infections.
U.S. Pat. No. 5,510,339 discloses the use of a topical anesthetic and a glucocorticoid to treat diseases such as bronchial asthma through inhalation therapy.
U.S. Pat. No. 4,478,822 discloses a system for delivering drugs including dexamethasone and procaine directly to a body cavity.
None of the abovementioned prior art citations, taken singly or in combination, appear to describe the present invention as claimed.
SUMMARY OF THE INVENTION
This invention comprises a generic formulation of procaine hydrochloride and dexamethasone sodium phosphate which is injected intramuscularly at certain dosages and regulated dosing intervals. This formulation has its broad spectrum use in treating viral infections, mainly AIDS, Dengue fever and influenza
Accordingly, it is a general objective of the present invention to provide a treatment for a broad spectrum of viral diseases which is quickly effective, does not induce serious side effects and can be simply administered in multiple, intramuscular, low volume doses.
Another objective of the present invention is to provide a formulation that can be quickly released for general use since the formulation is comprised of FDA approved generic drugs.
It is still another objective of the present invention to provide a treatment for viral diseases where a patient can experience a short recovery time.
Yet another objective of the present invention is to provide a viral disease treatment that is both easily portable and available in packaged form for immediate use. These and other objectives of the present invention will become readily apparent upon further review of the description of the present invention which follows.
BRIEF DESCRIPTION OF THE DRAWINGS
There are no drawings in this case.
REFERENCES:
patent: 4478822 (1984-10-01), Haslam
patent: 5492901 (1996-02-01), Fahunan
patent: 5510339 (1996-04-01), Gleich
patent: 5837729 (1998-11-01), Bourinhaiar
patent: 5922340 (1999-07-01), Berde
Bhargava et al., “Jaipur block in postherpetic neuralgia.” International Journal of Dermatology, vol. 37(6), pp. 465-468, 1998.*
Badio Barbara
Greenberg Barbara R.
LandOfFree
Injection viral treatment does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Injection viral treatment, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Injection viral treatment will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2519770